Designation applies to the treatment of adult patients with recurrent or metastatic head and neck squamous cell carcinoma ...
The funding comes as Eikon, run by former Merck research chief Roger Perlmutter, has started a Phase 3 trial testing one of its cancer drugs against Keytruda.
Merck warns Keytruda faces IRA price cuts from 2028, alongside patent expiry and biosimilar competition. Drug hit $29.5B ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback